Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Zak

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2013
A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitorsSue J Sohn, Kathy Barrett, Anne Van Abbema, et al.
Bioorganic & Medicinal Chemistry Letters|October 31, 2012
Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2Sharada Labadie, Peter S Dragovich, Kathy Barrett, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2013
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1Christopher A Hurley, Wade S Blair, Richard J Bull, et al.
Journal of Medicinal Chemistry|July 18, 2013
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitorsXiaozhang Zheng, Paul Bauer, Timm Baumeister, et al.
Journal of Medicinal Chemistry|January 11, 2014
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Anthony M Giannetti, Xiaozhang Zheng, Nicholas J Skelton, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2015
Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubilityMark Zak, Bianca M Liederer, Deepak Sampath, et al.
ACS Central Science|October 3, 2022
Correction to "An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative Infections"Erica N Parker, Brett N Cain, Behnoush Hajian, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2019
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signalingMark Zak, Emily J Hanan, Patrick Lupardus, et al.
Journal of Medicinal Chemistry|May 18, 2012
Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitorsJanusz J Kulagowski, Wade Blair, Richard J Bull, et al.
Science Translational Medicine|November 23, 2018
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthmaHart S Dengler, Xiumin Wu, Ivan Peng, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2013
A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitorsSue J Sohn, Kathy Barrett, Anne Van Abbema, et al.
Bioorganic & Medicinal Chemistry Letters|October 31, 2012
Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2Sharada Labadie, Peter S Dragovich, Kathy Barrett, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2013
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1Christopher A Hurley, Wade S Blair, Richard J Bull, et al.
Journal of Medicinal Chemistry|July 18, 2013
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitorsXiaozhang Zheng, Paul Bauer, Timm Baumeister, et al.
Journal of Medicinal Chemistry|January 11, 2014
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Anthony M Giannetti, Xiaozhang Zheng, Nicholas J Skelton, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2015
Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubilityMark Zak, Bianca M Liederer, Deepak Sampath, et al.
ACS Central Science|October 3, 2022
Correction to "An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative Infections"Erica N Parker, Brett N Cain, Behnoush Hajian, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2019
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signalingMark Zak, Emily J Hanan, Patrick Lupardus, et al.
Journal of Medicinal Chemistry|May 18, 2012
Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitorsJanusz J Kulagowski, Wade Blair, Richard J Bull, et al.
Science Translational Medicine|November 23, 2018
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthmaHart S Dengler, Xiumin Wu, Ivan Peng, et al.
Pageof 4